2 news items
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
DAWN
6 May 24
compensation expense of $9.4 million. Upcoming Events 2024 American Society of Clinical Oncology
Day One's OJEMDAâ„¢ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
DAWN
23 Apr 24
were presented in November 2023 at the Society for Neuro-Oncology meeting through two oral plenary presentations and in parallel through a publication
- Prev
- 1
- Next